Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications

Krishna J Rocha-Singh, Thomas Zeller, Michael R Jaff, Krishna J Rocha-Singh, Thomas Zeller, Michael R Jaff

Abstract

Vascular calcification (VC), particularly medial (Mönckeberg's medial sclerosis) arterial calcification, is common in patients with diabetes mellitus and chronic kidney disease and is associated with increased cardiovascular morbidity and mortality. Although, the underlying pathophysiological mechanisms and genetic pathways of VC are not fully known, hypocalcemia, hyperphosphatemia, and the suppression of parathyroid hormone activity are central to the development of vessel mineralization and, consequently, bone demineralization. In addition to preventive measures, such as the modification of atherosclerotic cardiovascular risk factors, current treatment strategies include the use of calcium-free phosphate binders, vitamin D analogs, and calcium mimetics that have shown promising results, albeit in small patient cohorts. The impact of intimal and medial VC on the safety and effectiveness of endovascular devices to treat symptomatic peripheral arterial disease (PAD) remains poorly defined. The absence of a generally accepted, validated vascular calcium grading scale hampers clinical progress in assessing the safety and utility of various endovascular devices (e.g., atherectomy) in treating calcified vessels. Accordingly, we propose the peripheral arterial calcium scoring system (PACSS) and a method for its clinical validation. A better understanding of the pathogenesis of vascular calcification and the development of optimal medical and endovascular treatment strategies are crucial as the population ages and presents with more chronic comorbidities.

Keywords: atherosclerosis; peripheral artery disease; vascular calcification.

© 2014 The Authors. Catheterization and Cardiovascular Interventions. Published by Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
Schematic diagram depicting multiple mechanisms leading to vascular calcification.
Figure 2
Figure 2
The fluoroscopic (panel A) and digital subtraction angiographic (panel B) appearance of severe calcification involving the SFA.
Figure 3
Figure 3
The fluoroscopic (panel A), Duplex ultrasonographic (panel B) and surgical appearance (panels C,D) of severe vascular calcification in a 64 year old diabetic female with symptomatic peripheral arterial disease. Severe circumferential calcification involves the common femoral artery (panel A, black arrows). Sonographic “drop-out,” seen as voids in the sonographic signal, is caused by dense calcification (panel B, white arrows). Common femoral artery incised during endarterectomy demonstrating densely calcified segment (black arrows, panel C) and after excision (panel D).

References

    1. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khana R. Vascular ossification—Calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis—Calcific uremic arteriolopathy: The emerging role of sodium thiosulfate. Cardiovasc Diabetol. 2005;4:4.
    1. Sage A, Tintut Y, Demer L. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol. 2010;7:528–536.
    1. Karwowski W, Naumnik B, Szczepański M, Myśliwiec M. The mechanism of vascular calcification—A systematic review. Med Sci Monit. 2012;18:RA1–RA11.
    1. Nitta K. Vascular calcification in patients with chronic kidney disease. Ther Apher Dial. 2011;15:513–521.
    1. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol. 2004;15:2959–2964.
    1. Abedin M, Tintut Y, Demer L. Vascular calcification: Mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004;24:1161–1170.
    1. Shao JS, Cheng SL, Sadhu J, Towler DA. Inflammation and the osteogenic regulation of vascular calcification: A review and perspective. Hypertension. 2010;55:579–592.
    1. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47:921–929.
    1. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: An epidemiologic view. Diabetes Metab Rev. 1987;3:463–524.
    1. Edmonds ME, Morrison N, Laws JW, Watkins PJ. Medial arterial calcification and diabetic neuropathy. Br Med J (Clin Res Ed) 1982;284:928–930.
    1. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: The killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009;20:1453–1464.
    1. Amann K. Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1599–1605.
    1. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95:560–567.
    1. Galan C, Jardín I, Dionisio N, Salido G, Rosado JA. Role of oxidant scavengers in the prevention of Ca2+ homeostasis disorders. Molecules. 2010;15:7167–7187.
    1. Kaneto H, Katakami N, Matsuhisa M, Matsuoka TA. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediat Inflamm. 2010;2010:453892.
    1. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: Key roles for calcium and phosphate. Circ Res. 2011;109:697–711.
    1. Bowman M, McNally E. Genetic pathways in vascular calcification. Trends Cardiovasc Med. 2012;22:93–98.
    1. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: Morbidity and mortality implications. Circulation. 2006;114:688–699.
    1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States. Results from the National Health and Nutrition Examination Survery, 1999–2000. Circulation. 2004;110:728–743.
    1. Belch JJ, Topol EJ, Agnelli F, Bertrand M, Califf RM, Clement DL, Creager MA, Easton JD, Gavin JR. Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, Weber MA. Critical issues in peripheral arterial disease detection and management: A call to action for the Prevention of Atherothrombotic Disease Network. Arch Intern Med. (3) 2003;163:884–892.
    1. Hirsch AT, Criqui MH, Treat-Jacobsen D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–1324.
    1. Allison MA, Criqui MH, Wright M. Patterns and risk factors for systemic calcified atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:331–336.
    1. Rifkin DE, Ix JH, Wassel CL, Criqui MH, Allison MA. Renal artery calcification and mortality among clinically asymptomatic adults. J Am Coll Cardiol. 2012;60:1079–1085.
    1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WRC, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, Jr, White CJ, White J, White RA. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society foe Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease) Circulation. 2006;113:e463–e654.
    1. Josephs SC, Rowley HA, Rubin GD. Atherosclerotic Peripheral Vascular Disease Symposium II. Vascular magnetic resonance and computed tomographic imaging; for Writing Group 3. Circulation. 2008;118:2837–2844.
    1. Haydar AA, Hujairi NM, Covic AA, Pereira D, Rubens M, Goldsmith DJ. Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: A study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant. 2004;19:2307–2312.
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int Suppl. 2009;113:S1–S130.
    1. Weinberg I, Giri J, Calfon M, Hawkins BM, Weinberg MD, Margey R, Hannon K, Schainfeld RM, Jaff MR. Anatomic correlates of supra-normal ankle brachial indices. Catheter Cardiovasc Intervent. 2013;81:1025–1030.
    1. London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul MC. Association of bone density, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008;19:1827–1835.
    1. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–1824.
    1. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients; for the Treat to Goal Working Group. Kidney Int. 2002;62:245–252.
    1. Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalatar-Zadeh K, Ahmadzadeh S. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: A randomized controlled trial. Am J Kidney Dis. 2012;59:58–66.
    1. Garcia-Lopes MG, Pillar R, Kamimura MA, Rocha LA, Canziani ME, Carvalho AB, Cuppari L. Cholecalciferol supplementation in chronic kidney disease: Restoration of vitamin D status and impact on parathyroid hormone. Ann Nutr Metab. 2012;61:74–82.
    1. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: A meta-analysis of prospective studies. Am J Kidney Dis. 2011;58:374–382.
    1. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J. The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis; for the ADVANCE study group. Nephrol Dial Transplant. 2011;26:1327–1339.
    1. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793–1800.
    1. Sianos G, Morel MA, Kappetein A, Morice M, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell M, Mohr F, Serruys P. The SYNTAX Score: An angiographic tool grading the complexity of coronary artery disease. Eurointervention. 2005;1:219–227.
    1. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty: Factors influencing long-term success. Circulation. 1991;83(Suppl 2):I70–I80.
    1. Bausback Y, Botsios S, Flux J, Werner M, Schuster J, Aithal J, Varcoe R, Bräunlich S, Ulrich M, Scheinert D, Schmidt A. Outback catheter for femoropopliteal occlusions: immediate and long-term results. J Endovasc Ther. 2011;18:13–21.
    1. Scheinert D, Grummt L, Piorkowski M, Sax J, Scheinert S, Ulrich M, Werner M, Bausback Y, Braunlich S, Schmidt A. A novel self-expanding interwoven nitinol stent for complex femoropopliteal lesions: 24-month results of the SUPERA SFA registry. J Endovasc Ther. 2011;18:745–752.
    1. Claire D, Roberts D. Treatment of severely calcified femoropopliteal lesions with plaque excision and embolic protection: DEFINITIVE Ca++ J Vasc Interv Radiol. 2011;22:1785. e2.
    1. Das T, Mustapha J, Indes J, Vorhies R, Beasley R, Doshi N, Adams G. Technique optimization of orbital atherectomy in calcified peripheral lesions of the lower extremity: The CONFIRM series, a prospective, multicenter registry. Catheter Cardiovasc Interv. 2014;83:115–122.
    1. Kim J, Ahanchi S, Panneton J. Identifying the target lesions for 245 laser angioplasty cases and a review of the literature. Vasc Endovasc Surg. 2012;46:640–647.
    1. Zeller T, Krankenberg H, Steinkamp H, Rastan A, Sixt S, Sievert H, Minar E, Bosier M, Peeters P, Balzer O, Gray W, Tubler T, Wissgott C, Schwarzwalder U, Scheinert D. One-year outcome of percutaneous rotational percutaneous atherectomy with aspiration in infrainginual peripheral arterial occlusive disease: The multicenter Pathway PVD Trial. J Endovasc Ther. 2009;16:653–662.
    1. Shrikhande G, McKinsey J. Use and abuse of atherectomy: Where should it be used? J Vasc Surg. 2008;21:204–209.
    1. Todd K, Ahanchi S, Maurer C, Kim J, Chipman C, Panneton J. Atherectomy offers no advantage over balloon angioplasty in tibial interventions for critical limb ischemia. J Vasc Surg. 2013;58:941–948.
    1. Fanelli F. Is There a Role for DEB in Calcified Arteries? Leipzig. Germany: LINC Interventional Congress; 2013.
    1. Scheller B, Speck U, Schmitt A, et al. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003;42:1415–1420.
    1. Speck U, Scheller B, Abramjuk C, et al. Neointima inhibition: Comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology. 2006;240:411–418.
    1. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary artery disease. N Engl J Med. 1987;316:1371–1375.
    1. Cioppa A, Stabile E, Popusoi G, et al. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: One-year single centre clinical results. Cardiovasc Revasc Med. 2012;13:219–223.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir